Last reviewed · How we verify

Ritlecitinib 100 mg (ritlecitinib-100-mg)

Pfizer Inc. · Phase 2 active Quality 5/100

Ritlecitinib 100 mg (generic name: ritlecitinib-100-mg) is a drug developed by Pfizer Inc.. It is currently in Phase 2 development.

At a glance

Generic nameritlecitinib-100-mg
SponsorPfizer Inc.
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ritlecitinib 100 mg

What is Ritlecitinib 100 mg?

Ritlecitinib 100 mg (ritlecitinib-100-mg) is a pharmaceutical drug developed by Pfizer Inc..

Who makes Ritlecitinib 100 mg?

Ritlecitinib 100 mg is developed by Pfizer Inc. (see full Pfizer Inc. pipeline at /company/pfizer).

What is the generic name of Ritlecitinib 100 mg?

ritlecitinib-100-mg is the generic (nonproprietary) name of Ritlecitinib 100 mg.

What development phase is Ritlecitinib 100 mg in?

Ritlecitinib 100 mg is in Phase 2.

What are the side effects of Ritlecitinib 100 mg?

Common side effects of Ritlecitinib 100 mg include Atrioventricular block first degree, Vessel puncture site pain, Arthralgia, Abdominal pain, Diarrhoea, Chills.

Related